Patient-oriented biomedical investigation related to diagnosis, disease mechanisms, monitoring disease activity and new therapeutic approaches in rheumatic disease is the hallmark of the Johns Hopkins Division of Rheumatology. This research is structured around well-established disease-specific Centers of Excellence in scleroderma (Dr. Fred Wigley), lupus (Dr. Michelle Petri), arthritis (Dr. Joan Bathon), and vasculitis (Dr. John Stone). These clinical cohorts are coupled closely with a robust basic science program directed by Drs. Antony Rosen and Livia Casciola-Rosen. In recent years, this program has received outstanding institutional support, enabling significant growth, investment in shared equipment and infrastructure, and the initiation of multiple synergistic projects both within and outside the Division. Our Rheumatic Disease Research Core Center (RDRCC) proposal capitalizes upon the strong biomedical research base within the Division of Rheumatology, as well as additional outstanding talent from the broader scientific community at Johns Hopkins. The Hopkins RDRCC proposal comprises an Administrative Core (Core A) led by Drs. Antony Rosen and John Stone, and includes 2 Scientific Cores: 1) a Bioassay Core (Core B), led by Drs. James Mahoney, Mark Soloski, and Livia Casciola-Rosen;and 2) a Genotyping/Genomics Core (Core C), led by Dr. Kathleen Barnes, designed to foster new research within and beyond the Division's Disease Centers. Core A will promote interdisciplinary research through the cores, provide assistance with financial management, provide information technology solutions to maximize efficiency of translational research, and coordinate program enrichment activities. The Administrative core will also manage the Pilot and Feasibility program. Pilot studies chosen for the first year are tightly linked to the disease Centers and Cores. Pilot #1 will optimize assays to quantify clearance of apoptotic cells directly ex vivo in pediatric SLE patients. Pilot #2 will explore the association of genetic polymorphisms in granzyme B with specific phenotypes in scleroderma. Core B will provide assistance with patient sample acquisition, processing, storage, and distribution, as well as the provision of multiple immunological assays, including FACS, ELISA, immunohistology, and multiplex cytokine assays. Core C will perform, analyze, and interpret gene expression studies in a variety of human disease and control tissues and some mouse models. Core C will also oversee the design, performance and analysis of genetic association studies in well-defined human rheumatic phenotypes.
This Rheumatic Disease Research Core Center provides systems and infrastructure to facilitate efficient research on humans with autoimmune rheumatic diseases. The synergies arising from coupling the diverse and well-resourced research base to the unusually rich collection of prospectively collected data from patients with rheumatic diseases through provision of central Cores provides unprecedented opportunities to enhance and accelerate discovery into the causes, mechanisms, diagnosis, therapy and prevention in these diseases.
|Mecoli, Christopher A; Delev, Nikolay G; Bingham 3rd, Clifton O (2016) Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter? Clin Rheumatol 35:3053-3056|
|Bouquet, Jerome; Soloski, Mark J; Swei, Andrea et al. (2016) Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease. MBio 7:e00100-16|
|Bingham 3rd, Clifton O; Bartlett, Susan J; Merkel, Peter A et al. (2016) Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. Qual Life Res 25:2109-16|
|McMahan, Zsuzsanna H; Cottrell, Tricia R; Wigley, Fredrick M et al. (2016) Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells. Arthritis Rheumatol 68:2540-9|
|Cappelli, Laura C; Shah, Ami A; Bingham 3rd, Clifton O (2016) Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open 2:e000321|
|Fava, Andrea; Cimbro, Raffaello; Wigley, Fredrick M et al. (2016) Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. Arthritis Res Ther 18:99|
|McMahan, Zsuzsanna H; Wigley, Fredrick M; Casciola-Rosen, Livia (2016) Increased risk of digital vascular events in scleroderma patients who have both anti-centromere and anti-interferon-inducible protein 16 antibodies. Arthritis Care Res (Hoboken) :|
|Park, Jin Kyun; Fava, Andrea; Carrino, John et al. (2016) Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis. Arthritis Rheumatol 68:201-9|
|Xu, George J; Shah, Ami A; Li, Mamie Z et al. (2016) Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci U S A 113:E7526-E7534|
|Birnbaum, Julius; Atri, Nidhi M; Baer, Alan N et al. (2016) The Relationship Between the Neuromyelitis Optica Spectrum Disorder and SjÃ¶gren's Syndrome: Central Nervous System Extraglandular Disease or Unrelated, Co-occurring Autoimmunity? Arthritis Care Res (Hoboken) :|
Showing the most recent 10 out of 94 publications